Recent Updates
Recently added Catalysts
IOVA Negative Sentiment

IOVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Iovance Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Iovance Biotherapeutics, Inc. is facing an investigation from Bragar Eagel & Squire, P.C. regarding potential violations of federal securities laws. This comes on the heels of the company's first-quarter financial results, which showed a sharp decrease in product revenue and significant cuts to its revenue guidance for the full fiscal year. The stock has responded negatively to these developments, indicating potential investor concerns and legal implications.
Price reaction · baseline $1.79 (2025-05-13 close) · hit after-hours · 3 other IOVA headline(s) in the window, move may be shared
day 0 close · peak
-4.7%

Market Sentiment Analysis

CONCERNS & RISKS

  • Iovance's quarterly product revenue fell significantly from $73.7 million to $49.3 million.
  • The company drastically revised its full-year revenue guidance down by over 40%.
  • Stock dropped after the release of the disappointing financial results on heavy trading volume.
  • The investigation may indicate potential legal challenges for the company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+126%
120-day peak, hindsight
Typical move
6.2%
average across 3 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
LN-145
Phase 2 · Squamous Cell Carcinoma of the Head and Neck

Full Press Release Details

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ:IOVA) on behalf of Iovance stockholders. Our investigation concerns whether Iovance has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. Iovance also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. The Company stated it was "revising full-year 2025 revenue guidance to reflect recent launch dynamics" of the Company's T cell immunotherapy, Amtagvi® (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. Following this news, Iovance stock dropped on unusually heavy trading volume.
If you purchased or otherwise acquired Iovance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

The firm is investigating potential claims against Iovance Biotherapeutics for possible violations of federal securities laws.

What recent financial results did Iovance disclose?

Iovance reported Q1 2025 product revenue of $49.3 million, down from $73.7 million.

How much did Iovance reduce its revenue guidance for 2025?

The company slashed its 2025 revenue guidance from $450-$475 million to $250-$300 million.

What affected Iovance's stock performance recently?

Iovance's stock dropped significantly following the announcement of its reduced revenue guidance.

How can Iovance stockholders get more information?

Stockholders can contact Bragar Eagel & Squire via email or phone for more information.

Last updated: May 14, 2025